Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753859 | 0.82 | HTR1A (0.46) | HTR2AHTR2CALDH1A1NPSR1CETP | |
| SCHEMBL5752490 | 0.82 | SLC1A1 (0.44) | SLC1A1KDM4EALDH1A1NPSR1PPARG | |
| SCHEMBL5750609 | 0.81 | HTR2A (0.56) | HTR2AHTR2CHTR2BCETP | |
| SCHEMBL5749572 | 0.81 | CETP (0.48) | CETP | |
| SCHEMBL5751847 | 0.79 | HTR2A (0.36) | HTR2AHTR2CHTR2BSLC1A1REN | |
| SCHEMBL5750636 | 0.79 | HTR2A (0.47) | HTR2AHTR2CHTR2BSLC1A1CETP | |
| SCHEMBL5752731 | 0.78 | CETP (0.46) | CETP | |
| SCHEMBL5750935 | 0.78 | CETP (0.38) | HTR2AHTR2CHTR2BSLC1A1KDM4E | |
| SCHEMBL5752561 | 0.76 | ADRA2A (0.40) | HTR2AHTR2CHTR2BSLC1A1KDM4E | |
| SCHEMBL5752681 | 0.76 | CYP17A1 (0.44) | HTR2AHTR2CHTR2BHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | HTR2A 705/4885HTR2C 770/4885HTR2B 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.